<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576587</url>
  </required_header>
  <id_info>
    <org_study_id>13-594</org_study_id>
    <secondary_id>R01HL109493</secondary_id>
    <nct_id>NCT02576587</nct_id>
  </id_info>
  <brief_title>Influence of Sleep Apnea on Risk of Atrial Fibrillation</brief_title>
  <acronym>Safebeat</acronym>
  <official_title>Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation study.

      The study involves a case control design to investigate the extent to which there is an
      independent relationship of sleep disordered breathing (SDB) and paroxysmal atrial
      fibrillation (PAF). Cases will be defined as clinically identified patients with PAF and
      controls as those without AF. In order to rigorously address important biologic confounding
      influences, the cases and controls will be individually matched based upon age, gender, race,
      and body mass index. Those participants with both PAF and SDB (Apnea Hypopnea Index, AHI&gt;=15)
      will be asked to return for a follow up exam after 3 months of SDB treatment in the Clinical
      Research Unit (CRU) for collection of the same measures collected at the baseline exam to
      observe for any significant changes with the purpose of collecting effect size data to inform
      future clinical trials.

      The total duration of the study is 4 years. The duration for any individual participant is up
      to from one to 13 weeks months, including a 3-month treatment period for those with moderate
      to severe SDB, i.e. AHI&gt;15.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep-disordered breathing (SDB) is common in patients with cardiovascular disease and its
      attendant hypoxemia and autonomic dysfunction create a milieu that is likely to enhance AF
      propensity. Thus, SDB may represent a novel target for AF prevention and treatment
      strategies. Although our prior cross-sectional work has shown a 2-4 fold higher odds of AF
      related to SDB, these and other reports have not included cardiac structural data or
      autonomic/biochemical measures, and have addressed only arrhythmic events occurring during an
      overnight sleep study. In this proposal, we will examine paroxysmal AF (PAF), an early stage
      risk factor for persistent AF, and relevant to this proposal because it occurs prior to
      extensive cardiac electrical remodeling/fibrosis.

      OUTLINE OF STUDY VISITS Baseline Visit (SA 1 and 2). After informed consent, eligible
      participants will be scheduled to arrive for an overnight visit in the CRU. During the
      evening, participants will undergo questionnaire administration, blood pressure measurements,
      and anthropometry. They will be provided dinner and undergo polysomnography (PSG). In the
      morning, participants will undergo fasting venipuncture, overnight urine collection, ECHO, 6
      minute walk test, vascular measures and blood pressure measurements. For those with PAF
      (cases), hook-up for continuous ECG monitoring will be performed along with education
      regarding how to handle the device and bathing instructions, etc. All measurements in the
      DCRU/CRU will be performed blinded to PAF status. The only unblinded staff will be a
      dedicated research assistant who will perform the ECG monitoring hook-up. Blinded staff will
      collect and process data and perform data entry. After the baseline visit, participants with
      PAF (n=150) will undergo hook-up of the ECG monitor and an activity monitor at the baseline
      visit to wear for a 7-21 day period.

      Follow-Up Visit (SA3). Those with SDB (AHI&gt;=15) without evidence of central apnea (central
      apnea index&gt;5) or Cheyne Stokes Respirations via baseline visit PSG and who have PAF will
      undergo the following. A 5-7 day home-based auto-titration (APAP, Respironics Autopap System
      One with humidifier) to identify the optimal positive airway pressure (PAP) setting will be
      performed (with settings 4-20cm H2O). At the end of the 5-7 day titration, the goal will be
      to identify the pressure that results in an AHI&lt;5 events/hour (optimally). The research
      assistant will re-set the device to deliver this optimal fixed pressure identified by the PI
      through the secure wireless web-site. An overnight DCRUCRU visit will be scheduled after 3
      months of wearing CPAP during which the same measures performed at the baseline visit will be
      collected.

      STUDY PROCEDURES 2-DIMENSIONAL DOPPLER ECHOCARDIOGRAPHY. Parasternal, apical and subcostal
      2-D views and apical 3D views will be obtained with transducer orientation and gain settings
      adjusted to optimally define endocardial surface of each cardiac chamber.

      POLYSOMNOGRAPHY (PSG). Procedure for PSG: Research PSG will be performed using the
      Compumedics E-series system (Abbottsford, AU) which will include 3 cortical encephalograms,
      bilateral electro-oculograms, a bipolar submental electromyogram, thoracic and abdominal
      respiratory inductance plethysmography, airflow (by nasal-oral thermocouple and nasal cannula
      pressure recording), oximetry (using highly sensitive finger pulse oximeter, sampling
      frequency 25Hz), electrocardiogram (ECG) at 250Hz (used to derive HRV measures of autonomic
      function); body position (mercury switch sensor), bilateral leg movements. EEGs are recorded
      at 125Hz. 3) 7-21 Day CONTINUOUS ECG MONITORING.

      Procedure: A 3-lead (2 channel), wireless, lightweight ECG monitoring device will be used to
      collect the ECG data over a 7-21 day period in those with PAF after the baseline and
      follow-up CRU visits.

      ACTIVITY MONITORING. Procedure: An accelerometer (GT3X+, Actigraph Co., Ft Walton Bch, Fl)
      will be used for 7-21 days, coincident with the time of continuous ECG monitoring.

      FASTING VENIPUNCTURE (52cc). Procedure: Phlebotomy will be performed the morning of the
      baseline and follow-up visits using standard techniques by trained research staff following
      written procedures. 6) DNA collection. Blood will be collected to extract RNA, which will be
      stored to test future hypotheses regarding genetic determinants of treatment response.

      OVERNIGHT URINE. Procedure: Overnight urine collection will be performed. ANTHROPOMETRY.
      Height (inches, cm), neck circumference (cm), waist circumference (cm), hip circumference
      (cm) will be obtained. Skinfolds are measured with calibrated metal calipers from 7 sites
      (chest, calf, thigh, calf, subscapular, midaxillary, suprailiac, abdominal).

      RESTING BLOOD PRESSURE (BP). BP will be measured after the participant has been sitting
      quietly for at least 5 minutes following standardized guidelines using a calibrated
      sphygmomanometer. Measurements will be repeated three times and recorded.

      QUESTIONNAIRES. The following will be collected: a) The Berlin Sleep Questionnaire, b)
      Epworth Sleepiness Scale, c) The Sleep Habits and Medical Condition Questionnaire d) The
      Medical Outcomes Survey-SF 36 (MOS-SF) e) Patient Health Questionnaire-9 (PHQ-9) f) Daily
      ECG/Activity Log g) Atrial Fibrillation Effect on Quality-of-life, a 20-item questionnaire
      that assesses the impact of atrial fibrillation on quality of life.

      6 Minute Walk Test. Baseline oxygen saturation and heart rate will be recorded. If oxygen
      saturation &gt;90%, then proceed with protocol. Using the BORG Scale record rate the symptoms of
      breathlessness and leg fatigue after a 6 minute walk at usual pace.

      Arterial Applanation Tonometry: Radial artery measurements will be performed after
      sphygmomanometric pressure is obtained with use of an applanation tonometry probe with a
      minimum of two consecutive measurements to obtain pulse wave analysis results. For pulse wave
      velocity, lead II ECG will be performed along with cardotid and femoral applanation
      tomometry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">February 22, 2017</completion_date>
  <primary_completion_date type="Actual">February 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Paroxymal Atrial Fibrillation (PAF)</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients with diagnosis of PAF were defined as cases. PAF is the primary outcome of baseline analysis, which aimed to quantify the association of sleep apnea and PAF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography Measures- Left Atrial Volume</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Echocardiography measurements were not available for some subjects due to image quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures- LA Volume Index</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Left atrial volume index (LAVI) is left atrial size indexed to Body surface area (BSA). The reference range of LAVI is 16-28 mL/m^2.
Mildly abnormal: 29-33 mL/m^2; Moderately abnormal: 34-39 mL/m^2; Severely abnormal: greater than or equal to 40 mL/m^2.
Echocardiography measurements were not available for some subjects due to image quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures- LA Systolic Strain by A4C View</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures- LA Systolic Strain by A2C View</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Measures- Pulse Wave Velocity</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Radial measurements were performed on the same arm using the SphygmoCor device after sphygmomanometric pressure was obtained with use of an applanation tonometry probe containing a solid state high fidelity Millar transducer over the radial artery with a minimum of two consecutive measurements to obtain pulse wave analysis results. For pulse wave velocity, lead II ECG (LL, LA, RA) was performed along with cardotid and femoral applanation tomometry. Orientation and pressure applied to the transducer were adjusted to optimize applanation of the artery between the transducer and the underlying tissue. Waveforms were processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia).)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Measures- Augmentation Index</measure>
    <time_frame>Baseline and 12 week follow up</time_frame>
    <description>Augmentation Index (Alx) is an indication of systemic arterial stiffness and measures the contributions of wave reflection to central systolic pressure. Scores vary based on age and gender and in a normal, healthy population research has shown can range from -10% or less up to 50%. A negative augmentation index suggests low artery stiffness (late arriving wave reflections) and a positive index is a reflection of increase artery stiffness (reflective wave arriving early in the cardiac cycle). Waveforms will be processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia) for this measurement.
It is calculated at the onset of reflected wave, Alx = AP/PP x 100. Alx = Augmentation Index, the percentage of the pulse pressure due to the AP; PP = Pulse Pressure; AP = Augmentation Pressure, the contribution of the reflected wave to the pulse pressure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">317</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Case (diagnosed with PAF)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
Cases found to have an apnea hypopnea index &gt;=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure</intervention_name>
    <description>For cases, those found to have moderate sleep apnea (AHI &gt;=15) will be place on CPAP therapy.</description>
    <arm_group_label>Case (diagnosed with PAF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for Cases:

        PAF defined by recurrent episodes of AF, which self-terminate within a 7-day period (based
        upon AHA consensus statement 77)

        Age 18-80 years

        Individuals able to participate in &gt; 2 overnight/daytime sleep and physiologic assessments
        over a 3 month period.

        Inclusion Criteria for Controls:

        Age 18 to 80 years

        Individuals in normal sinus rhythm (NSR) with no current AF or history of AF

        Individuals able to participate in an overnight/daytime sleep and physiologic assessment.

        Exclusion Criteria:

        Exclusion Criteria for Cases:

        PAF with rapid or uncontrolled rate (&gt;120bpm)

        Post-operative PAF

        History of cardiac ablation or successful electro-cardioversion for PAF (ablation for other
        arrhythmias such as AVNRT and if PAF persists after cardioversion is acceptable )

        Valvular stenosis, prosthesis or significant valvular insufficiency [i.e. those with
        moderate or greater severity of aortic stenosis (aortic valve area &lt;1.5 cm2), mitral
        regurgitation which is moderate or more severe in degree (&gt;20% regurgitant fraction) or
        moderate or greater severity mitral stenosis (mitral valve area &lt;1.5 cm2)]

        Atrial septal defect

        Infiltrative/restrictive cardiomyopathy

        Sick sinus syndrome

        Previously diagnosed SDB on specific SDB treatments (CPAP, oral appliances)

        Severe chronic insomnia

        Circadian rhythm disorder (e.g. shift work sleep disorder, delayed or advanced sleep phase
        syndrome)

        Insufficient sleep syndrome defined by reported sleep duration &lt; 4 hrs

        Supplemental oxygen use

        Unstable medical conditions (e.g., new onset or changing angina, a myocardial infarction or
        congestive heart failure exacerbation documented within the previous 3 months, systolic
        heart failure (Left Ventricular Ejection Fraction &lt; 35%), high grade cardiac
        dysrhythmia/heart block, stroke with functional limitations, uncontrolled hypertension
        (BP&gt;170/110), abdominal aneurysm &gt;5.5 cm or &gt;1 cm growth/year, uncontrolled diabetes
        mellitus (HbA1c&gt;9.0), pulmonary hypertension, non-skin cancer diagnosis or treatment within
        the previous year, end stage renal and hepatic failure, immunodeficiencies (HIV, HCV),
        uncontrolled hypo- or hyperthyroidism)

        Psychiatric disorders which are inadequately treated

        Compromised competence

        Alcohol abuse (currently drinks &gt;5 alcoholic drinks/day)

        Pregnancy

        Inability to provide informed consent

        Illicit drug use over last 6 months

        Rate controlling anti-arrhythmic medication (Classes I-III and V) with no further clinical
        occurrence of PAF

        Has a Pacemaker or Implantable cardioverter-defibrillator.

        Rationale for criteria: The goal of this study is to include those patients with PAF that
        is not secondary to the post-operative period or valvular disease and without ablation as
        these processes would result in alteration of atrial physiology and preclude assessment of
        independent SDB effects on AF which is independent of these conditions. Patients with sleep
        disorders will be excluded as sleep disorders may influence arrhythmogenesis. Those on
        treatment for SDB will be excluded because treatment would preclude assessment of SDB
        pathophysiologic effects on atrial arrhythmogenesis. Those with unstable medical conditions
        or rapid or uncontrolled heart rate will be excluded due to safety reasons.

        Note: Exclusion criteria for positive airway pressure (PAP) intervention: Central Apnea
        Index&gt;5 noted on baseline examination sleep study or evidence of Cheyne Stokes
        Respirations/periodic breathing (cyclical crescendo and decrescendo change in breathing
        amplitude).

        Exclusion Criteria for Controls:

        Current or history of AF, otherwise the same exclusion criteria listed for cases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reena Mehra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <results_first_submitted>April 11, 2018</results_first_submitted>
  <results_first_submitted_qc>July 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2018</results_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Reena Mehra, MD</investigator_full_name>
    <investigator_title>Director of Sleep Disorders Reseach, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02576587/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Case (Diagnosed With PAF)</title>
          <description>Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
Cases found to have an apnea hypopnea index &gt;=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.
Continuous Positive Airway Pressure: For cases, those found to have moderate sleep apnea (AHI &gt;=15) will be place on CPAP therapy.</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161">Total cases baseline visit</participants>
                <participants group_id="P2" count="156">Total controls baseline visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161">Baseline visit completed</participants>
                <participants group_id="P2" count="155">Baseline visit completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Equipment failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up Period (Case Only)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161">Completed baseline.</participants>
                <participants group_id="P2" count="155">Controls not eligible for follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Selected for Follow up</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not selected for follow up (AHI&lt;15)</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Controls not eligible for followup</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cases and controls completed baseline visit and having matched controls/cases were included in baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Case (Diagnosed With PAF)</title>
          <description>Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
Cases completed baseline and having matched controls were included in baseline data analysis.</description>
        </group>
        <group group_id="B2">
          <title>Controls</title>
          <description>Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
Controls completed baseline and having matched cases were included in baseline data analysis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="12"/>
                    <measurement group_id="B2" value="62" spread="12"/>
                    <measurement group_id="B3" value="61" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="7"/>
                    <measurement group_id="B2" value="32" spread="7"/>
                    <measurement group_id="B3" value="31" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apnea Hypopnea Index (AHI)</title>
          <description>AHI equals number of apnea and hypopnea breathing pauses divided by sleep duration in hours. It has a lower limit zero, but no upper limit. Greater AHI indicates higher severity of sleep apnea. The AHI values for adults are categorized as:
Normal: AHI&lt;5; Mild sleep apnea: AHI greater than or equal to 5 and &lt;15; Moderate sleep apnea: AHI greater than or equal to 15 and &lt;30; Severe sleep apnea: any AHI value greater than or equal to 30.
In this study, cases having AHI greater than or equal to 15 qualifies for follow-up.</description>
          <units>apneas plus hypopneas per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="B2" value="13" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="B3" value="12" lower_limit="4" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arousal Index</title>
          <description>Arousal index (AI) equals number of arousals divided by sleep duration in hours. Arousals are interruptions of sleep lasting 3 to 15 seconds, spontaneously or as a result of sleep disordered breathing or other sleep disorders. It has a lower limit zero, but no upper limit. The range of AI for adults varies by age, e.g. 10-12/hour are normal at age 20, 20-22/hour are normal at age 50-60.</description>
          <units>Arousals per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="B2" value="19" lower_limit="13" upper_limit="28"/>
                    <measurement group_id="B3" value="19" lower_limit="13" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Apnea Index</title>
          <description>Central apnea index (CAI) equals number of central apneas divided by sleep duration in hours. Greater central apnea index indicates higher severity of sleep apnea. It has a lower limit zero, but no upper limit. The CAI values for adults are categorized as:
Normal: CAI&lt;5; Mild sleep apnea: CAI greater than or equal to 5 and &lt;15; Moderate sleep apnea: CAI greater than or equal to 15 and &lt;30; Severe sleep apnea: any CAI value greater than or equal to 30.</description>
          <units>Central apneas per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0.4"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="0.4"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent sleep time with oxygen saturation&lt;90%</title>
          <units>percent of sleep time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="0.4" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B3" value="0.4" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Atrial Volume</title>
          <description>Increased left atrial volume and strain are known risk factors of AF and PAF.</description>
          <population>Echocardiography measurements were not available for some subjects due to image quality. If at least one of the matched case and control had missing value, this pair of subjects was not included in analysis.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="135"/>
                    <count group_id="B3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="48" upper_limit="77"/>
                    <measurement group_id="B2" value="51" lower_limit="45" upper_limit="71"/>
                    <measurement group_id="B3" value="60" lower_limit="46" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Atrial Volume Index</title>
          <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Left atrial volume index (LAVI) is left atrial size indexed to Body surface area (BSA). The reference range of LAVI is 16-28 mL/m^2.
Mildly abnormal: 29-33 mL/m^2; Moderately abnormal: 34-39 mL/m^2; Severely abnormal: greater than or equal to 40 mL/m^2.</description>
          <population>Echocardiography measurements were not available for some subjects due to image quality. If at least one of the matched case and control had missing value, this pair of subjects was not included in analysis.</population>
          <units>mL/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="134"/>
                    <count group_id="B2" value="134"/>
                    <count group_id="B3" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="23" upper_limit="37"/>
                    <measurement group_id="B2" value="28" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="B3" value="29" lower_limit="23" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Atrial Systolic Strain by apical four-chamber (A4C) view</title>
          <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber and two-chamber views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
          <population>Echocardiography measurements were not available for some subjects due to image quality. If at least one of the matched case and control had missing value, this pair of subjects was not included in analysis.</population>
          <units>percent of left atrial volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="107"/>
                    <count group_id="B3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="25" upper_limit="40"/>
                    <measurement group_id="B2" value="33" lower_limit="27" upper_limit="41"/>
                    <measurement group_id="B3" value="33" lower_limit="27" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Atrial Systolic Strain by apical two-chamber (A2C) view</title>
          <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber and two-chamber views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
          <population>Echo measurements were not available for some subjects due to image quality. If at least one of the matched case and control had missing value, this pair of subjects was not included in analysis.</population>
          <units>percent of left atrial volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="106"/>
                    <count group_id="B2" value="106"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="29" upper_limit="41"/>
                    <measurement group_id="B2" value="35" lower_limit="29" upper_limit="43"/>
                    <measurement group_id="B3" value="35" lower_limit="29" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Blood Pressure or Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Blood cholesterol</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of heart attack</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Calcium blocker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of beta blocker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any use of antihypertension medications</title>
          <description>Medications included Ace Inhibitors, Antihypertensive, Alpha-2 Blocker, Beta-Blocker, Calcium blocker, Diuretic and Nitrates.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="150"/>
                    <count group_id="B3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Paroxymal Atrial Fibrillation (PAF)</title>
        <description>Patients with diagnosis of PAF were defined as cases. PAF is the primary outcome of baseline analysis, which aimed to quantify the association of sleep apnea and PAF.</description>
        <time_frame>Baseline</time_frame>
        <population>Cases and controls who had matched control/case were included in baseline analysis. Only 150 cases were one-to-one matched with controls.</population>
        <group_list>
          <group group_id="O1">
            <title>Case (Diagnosed With PAF)</title>
            <description>Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
Cases found to have an apnea hypopnea index &gt;=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.
Continuous Positive Airway Pressure: For cases, those found to have moderate sleep apnea (AHI &gt;=15) will be place on CPAP therapy.</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Paroxymal Atrial Fibrillation (PAF)</title>
          <description>Patients with diagnosis of PAF were defined as cases. PAF is the primary outcome of baseline analysis, which aimed to quantify the association of sleep apnea and PAF.</description>
          <population>Cases and controls who had matched control/case were included in baseline analysis. Only 150 cases were one-to-one matched with controls.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Conditional logistic regression was used to assess the relationship of PAF and AHI on matched pairs of case and control.</non_inferiority_desc>
            <p_value>0.054</p_value>
            <method>Conditional logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.007</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Conditional logistic regression was used to assess the relationship of PAF and LA volume on matched pairs of case and control.</non_inferiority_desc>
            <p_value>0.014</p_value>
            <method>Conditional logistic regression</method>
            <method_desc>N = 270 (135 cases and 135 controls)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.007</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Conditional logistic regression was used to assess the relationship of PAF and LA volume index on matched pairs of case and control.</non_inferiority_desc>
            <p_value>0.030</p_value>
            <method>Conditional logistic regression</method>
            <method_desc>N=268 (134 cases and 134 controls)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Conditional logistic regression was used to assess the relationship of PAF and LA systolic strain apical four-chamber (A4C) on matched pairs of case and control.</non_inferiority_desc>
            <p_value>0.39</p_value>
            <method>Conditional logistic regression</method>
            <method_desc>N=214 (107 cases and 107 controls)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Conditional logistic regression was used to assess the relationship of PAF and LA systolic strain apical two-chamber (A2C) on matched pairs of case and control.</non_inferiority_desc>
            <p_value>0.49</p_value>
            <method>Conditional logistic regression</method>
            <method_desc>N=212 (106 cases and 106 controls)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiography Measures- Left Atrial Volume</title>
        <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Echocardiography measurements were not available for some subjects due to image quality.</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <population>Cases found to have an apnea hypopnea index &gt;=15 were asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.</population>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiography Measures- Left Atrial Volume</title>
          <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Echocardiography measurements were not available for some subjects due to image quality.</description>
          <population>Cases found to have an apnea hypopnea index &gt;=15 were asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="52" upper_limit="79"/>
                    <measurement group_id="O2" value="72" lower_limit="55" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>median of change</param_type>
            <param_value>3.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>Inter-Quartile Range of the change (post minus pre) is (-7.0, 13.7).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures- LA Volume Index</title>
        <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Left atrial volume index (LAVI) is left atrial size indexed to Body surface area (BSA). The reference range of LAVI is 16-28 mL/m^2.
Mildly abnormal: 29-33 mL/m^2; Moderately abnormal: 34-39 mL/m^2; Severely abnormal: greater than or equal to 40 mL/m^2.
Echocardiography measurements were not available for some subjects due to image quality.</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures- LA Volume Index</title>
          <description>Increased left atrial volume and strain are known risk factors of AF and PAF. Left atrial volume index (LAVI) is left atrial size indexed to Body surface area (BSA). The reference range of LAVI is 16-28 mL/m^2.
Mildly abnormal: 29-33 mL/m^2; Moderately abnormal: 34-39 mL/m^2; Severely abnormal: greater than or equal to 40 mL/m^2.
Echocardiography measurements were not available for some subjects due to image quality.</description>
          <units>mL/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="37"/>
                    <measurement group_id="O2" value="30" lower_limit="24" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>median of change</param_type>
            <param_value>1.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Inter-quartile range of the change (post minus pre) is (-2.0, 6.0).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures- LA Systolic Strain by A4C View</title>
        <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures- LA Systolic Strain by A4C View</title>
          <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
          <units>percentage of left atrial volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="24" upper_limit="46"/>
                    <measurement group_id="O2" value="29" lower_limit="23" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>median of change</param_type>
            <param_value>-3.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Inter-quartile range of the change (post minus pre) is (-8.0, -0.57).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures- LA Systolic Strain by A2C View</title>
        <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures- LA Systolic Strain by A2C View</title>
          <description>Left atrial systolic strain, a measure of left atrial remodeling which is inversely related to fibrosis in PAF, is measured by 2-dimensional echocardiography. Apical four-chamber (A4C) and two-chamber (A2C) views are the most commonly used approaches to measure the strain rate (%) of left atrial.</description>
          <units>percentage of left atrial volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="27" upper_limit="41"/>
                    <measurement group_id="O2" value="37" lower_limit="28" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>median of change</param_type>
            <param_value>-0.70</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Inter-quartile range of the change (post minus pre) is (-6.2, 10.7).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Measures- Pulse Wave Velocity</title>
        <description>Radial measurements were performed on the same arm using the SphygmoCor device after sphygmomanometric pressure was obtained with use of an applanation tonometry probe containing a solid state high fidelity Millar transducer over the radial artery with a minimum of two consecutive measurements to obtain pulse wave analysis results. For pulse wave velocity, lead II ECG (LL, LA, RA) was performed along with cardotid and femoral applanation tomometry. Orientation and pressure applied to the transducer were adjusted to optimize applanation of the artery between the transducer and the underlying tissue. Waveforms were processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia).)</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <population>Cases selected for follow-up and having available SphygmoCor measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Measures- Pulse Wave Velocity</title>
          <description>Radial measurements were performed on the same arm using the SphygmoCor device after sphygmomanometric pressure was obtained with use of an applanation tonometry probe containing a solid state high fidelity Millar transducer over the radial artery with a minimum of two consecutive measurements to obtain pulse wave analysis results. For pulse wave velocity, lead II ECG (LL, LA, RA) was performed along with cardotid and femoral applanation tomometry. Orientation and pressure applied to the transducer were adjusted to optimize applanation of the artery between the transducer and the underlying tissue. Waveforms were processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia).)</description>
          <population>Cases selected for follow-up and having available SphygmoCor measurements</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.7"/>
                    <measurement group_id="O2" value="10.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>mean of change</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.2</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Measures- Augmentation Index</title>
        <description>Augmentation Index (Alx) is an indication of systemic arterial stiffness and measures the contributions of wave reflection to central systolic pressure. Scores vary based on age and gender and in a normal, healthy population research has shown can range from -10% or less up to 50%. A negative augmentation index suggests low artery stiffness (late arriving wave reflections) and a positive index is a reflection of increase artery stiffness (reflective wave arriving early in the cardiac cycle). Waveforms will be processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia) for this measurement.
It is calculated at the onset of reflected wave, Alx = AP/PP x 100. Alx = Augmentation Index, the percentage of the pulse pressure due to the AP; PP = Pulse Pressure; AP = Augmentation Pressure, the contribution of the reflected wave to the pulse pressure.</description>
        <time_frame>Baseline and 12 week follow up</time_frame>
        <population>Cases selected for follow-up and having available SphygmoCor measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Case Baseline</title>
            <description>Case baseline measurements</description>
          </group>
          <group group_id="O2">
            <title>Case Follow-up</title>
            <description>Case follow-up measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Measures- Augmentation Index</title>
          <description>Augmentation Index (Alx) is an indication of systemic arterial stiffness and measures the contributions of wave reflection to central systolic pressure. Scores vary based on age and gender and in a normal, healthy population research has shown can range from -10% or less up to 50%. A negative augmentation index suggests low artery stiffness (late arriving wave reflections) and a positive index is a reflection of increase artery stiffness (reflective wave arriving early in the cardiac cycle). Waveforms will be processed using the SphygmoCor software (model EM3, version CvMS 9.0, Atcor Medical Pty, West Ryde, Australia) for this measurement.
It is calculated at the onset of reflected wave, Alx = AP/PP x 100. Alx = Augmentation Index, the percentage of the pulse pressure due to the AP; PP = Pulse Pressure; AP = Augmentation Pressure, the contribution of the reflected wave to the pulse pressure.</description>
          <population>Cases selected for follow-up and having available SphygmoCor measurements</population>
          <units>percentage of augmentation pressure</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="13.2"/>
                    <measurement group_id="O2" value="26.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t test was used to compare pre- and post- treatment outcomes.</method_desc>
            <param_type>mean of change</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.2</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected on all participants during their overnight visit. Participants (cases) which qualified for CPAP, adverse events were collected over a 3 month period while wearing CPAP.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Case (Diagnosed With PAF)</title>
          <description>Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
Cases found to have an apnea hypopnea index &gt;=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.
Continuous Positive Airway Pressure: For cases, those found to have moderate sleep apnea (AHI &gt;=15) will be place on CPAP therapy.</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure (went to ER)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructed Bowel</sub_title>
                <description>Hospitalized</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hit by Automobile</sub_title>
                <description>visit to ER</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache from prior car accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective Tummy Tuck Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Elective Ablation for Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Elective - Total Knee Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Rate 130-190 bpm</sub_title>
                <description>(Alerted form continuous ECG Monitor) Forgot to take medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Continuous ECG Alert</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>(A-fib noted)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>A-Fib went to ER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>A-fib with shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Runny nose with CPAP use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bloody nose (slight) upon wakening</sub_title>
                <description>(with CPAP use)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injured Knee in shower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nail puctured hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Twisted ankle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fell off motorcycle</sub_title>
                <description>cracked rib</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle and skeletal pain from Echocardiogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching/inflammation fron ECG pads</sub_title>
                <description>(From wearing continuous ECG)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Itching head from CPAP headwear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Poison Ivy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Reena Mehra</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-4946</phone>
      <email>mehrar@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

